content_image/187330.jpg content_image/187329.jpg
## Continuous Launch of New Products 

Having developed its own sales network in more than 50 countries around the world, Astellas has a well-balanced global business spanning the four regions of Japan, the Americas, EMEA and Asia & Oceania. In addition to global products, such as mirabegron and XTANDI, we also market distinctive new products in each region. These products underpin our growth and constitute one of our key strengths. 

## Expanding New Products in Japan 

Astellas has one of Japan’s top sales/marketing platforms, with a sales force of around 2,400 medical representatives (MRs). Our strong presence supports a broad portfolio that contains numerous growth drivers and new products. 

In 2014, we launched Suglat as Japan’s first SGLT2 inhibitor for the treatment of type 2 diabetes in April, fol- lowed by XTANDI in May. Both of these new products will support our future growth in Japan as we work to steadily increase their market penetration. 

In May 2013, we entered into a strategic alliance 

<img src='content_image/187330.jpg'>

* New product group: Total sales of products launched within the past three years. (ARGAMATE, Kiklin, Regnite, Gonax, Cimzia, Acofide) 

in Japan with Amgen Inc. to expand our product portfolio. Under this alliance, we will co-develop and co-commercialize five of Amgen’s pipeline medicines through our Tokyo-based joint venture, Amgen Astellas BioPharma KK. 

## Strengthening Our Sales Platform in Emerging Countries In emerging countries, we are looking to reinforce our 

sales platform, notably in China and Russia. We expect emerging markets to continue growing, but governments in these countries are implementing measures to curb healthcare spending at an even faster rate than developed countries. National and regional market characteristics also vary greatly. 

While taking the characteristics and changes in busi- ness conditions in these emerging markets into account, our strategy is to focus on high-value-added new drugs, just as in advanced economies. Our policy is to develop operations steadily to help generate reliable future  earnings streams. 

<img src='content_image/187329.jpg'>

* Other: Total sales of affiliates located in emerging pharmaceutical markets as defined by IMS Health Incorporated, excluding China and Russia. (Brazil, India, Turkey, Thailand, Vietnam, Indonesia, Poland, Romania, South Africa) 

